Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats dementia of the Alzheimer’s type. Sold as Aricept, Aricept Odt, Adlarity. Every FDA application for this active ingredient: 5 branded and 48 generic.
As of Nov 15, 2026, FDA lists 53 applications for Donepezil Hydrochloride (sold as Aricept, Aricept Odt, Adlarity), first approved Nov 25, 1996, with 3 new uses approved and 1 published complete response letter.
First approved: Nov 25, 1996
Applications: 53
New uses approved: 3
Complete response letters: 1
Medicare spending, 2025: $112M
First approved in Japan: Dec 23, 2022
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
DONEPEZIL HCL 10 MG TABLET: $0.049 per unitGeneric · -2% in a year
DONEPEZIL HCL 23 MG TABLET: $0.771 per unitGeneric · -4% in a year
DONEPEZIL HCL 5 MG TABLET: $0.043 per unitGeneric · +1% in a year
DONEPEZIL HCL ODT 10 MG TABLET: $0.307 per unitGeneric · -5% in a year
DONEPEZIL HCL ODT 5 MG TABLET: $0.276 per unitGeneric · -3% in a year
Approvals in Japan (PMDA)
First approved in Japan 313 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Allydone, new ingredientDrugs with a new active ingredient indicated for inhibiting progression of symptoms of dementia in patients with Alzheimer's disease. · Teikoku Seiyaku Co., Ltd. · Dec 23, 2022
AriceptDrugs with a new additional indication and a new dosage for inhibiting progress of dementia symptoms in patients with dementia with Lewy bodies. · Eisai Co., Ltd. · Sep 19, 2014
Clinical Trials
29 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sun Pharm Industries
Zydus Pharms USA Inc
Novitium Pharma
Wockhardt
Strides Pharma
Apotex
Accord Hlthcare
Zydus Lifesciences
Lupin
Par Pharm